Validation of an electronic frailty index with electronic health records: eFRAGICAP index.

Cohort Studies Electronic Health Records Frail Elderly Geriatric Assessment Primary Health Care Survival Analysis Validation Study

Journal

BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548

Informations de publication

Date de publication:
07 05 2022
Historique:
received: 17 02 2022
accepted: 21 04 2022
entrez: 7 5 2022
pubmed: 8 5 2022
medline: 11 5 2022
Statut: epublish

Résumé

To create an electronic frailty index (eFRAGICAP) using electronic health records (EHR) in Catalunya (Spain) and assess its predictive validity with a two-year follow-up of the outcomes: homecare need, institutionalization and mortality in the elderly. Additionally, to assess its concurrent validity compared to other standardized measures: the Clinical Frailty Scale (CFS) and the Risk Instrument for Screening in the Community (RISC). The eFRAGICAP was based on the electronic frailty index (eFI) developed in United Kingdom, and includes 36 deficits identified through clinical diagnoses, prescriptions, physical examinations, and questionnaires registered in the EHR of primary health care centres (PHC). All subjects > 65 assigned to a PHC in Barcelona on 1st January, 2016 were included. Subjects were classified according to their eFRAGICAP index as: fit, mild, moderate or severe frailty. Predictive validity was assessed comparing results with the following outcomes: institutionalization, homecare need, and mortality at 24 months. Concurrent validation of the eFRAGICAP was performed with a sample of subjects (n = 333) drawn from the global cohort and the CFS and RISC. Discrimination and calibration measures for the outcomes of institutionalization, homecare need, and mortality and frailty scales were calculated. 253,684 subjects had their eFRAGICAP index calculated. Mean age was 76.3 years (59.5% women). Of these, 41.1% were classified as fit, and 32.2% as presenting mild, 18.7% moderate, and 7.9% severe frailty. The mean age of the subjects included in the validation subsample (n = 333) was 79.9 years (57.7% women). Of these, 12.6% were classified as fit, and 31.5% presented mild, 39.6% moderate, and 16.2% severe frailty. Regarding the outcome analyses, the eFRAGICAP was good in the detection of subjects who were institutionalized, required homecare assistance, or died at 24 months (c-statistic of 0.841, 0.853, and 0.803, respectively). eFRAGICAP was also good in the detection of frail subjects compared to the CFS (AUC 0.821) and the RISC (AUC 0.848). The eFRAGICAP has a good discriminative capacity to identify frail subjects compared to other frailty scales and predictive outcomes.

Identifiants

pubmed: 35525922
doi: 10.1186/s12877-022-03090-8
pii: 10.1186/s12877-022-03090-8
pmc: PMC9080132
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

404

Informations de copyright

© 2022. The Author(s).

Références

J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
Stat Med. 2004 Jul 15;23(13):2109-23
pubmed: 15211606
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Br J Gen Pract. 2017 Nov;67(664):e751-e756
pubmed: 28947622
Med Clin (Barc). 2012 May 19;138(14):617-21
pubmed: 22444996
Mech Ageing Dev. 2021 Sep;198:111546
pubmed: 34324923
J Am Med Dir Assoc. 2015 Jul 1;16(7):603-6
pubmed: 25769962
Age Ageing. 2016 May;45(3):353-60
pubmed: 26944937
Inform Prim Care. 2011;19(3):135-45
pubmed: 22688222
Aging Clin Exp Res. 2019 May;31(5):653-660
pubmed: 30132204
BMC Geriatr. 2008 Sep 30;8:24
pubmed: 18826625
BMC Geriatr. 2015 Jul 30;15:92
pubmed: 26224138
J Nutr Health Aging. 2016;20(6):653-8
pubmed: 27273356
Age Ageing. 2019 Mar 1;48(2):273-277
pubmed: 30590413
J Gerontol A Biol Sci Med Sci. 2022 Jan 7;77(1):148-154
pubmed: 33885746
J Nutr Health Aging. 2021;25(2):155-159
pubmed: 33491028
Ann Geriatr Med Res. 2020 Jun;24(2):62-74
pubmed: 32743326
Age Ageing. 2021 Jan 8;50(1):96-104
pubmed: 33068107
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
ScientificWorldJournal. 2001 Aug 08;1:323-36
pubmed: 12806071
J Nutr Health Aging. 2015 Jun;19(6):669-72
pubmed: 26054503
J Am Med Dir Assoc. 2013 Jun;14(6):392-7
pubmed: 23764209
J Gerontol A Biol Sci Med Sci. 2013 Mar;68(3):301-8
pubmed: 22843671
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
J Am Med Dir Assoc. 2016 Mar 1;17(3):188-92
pubmed: 26805753
BMC Geriatr. 2020 Oct 7;20(1):393
pubmed: 33028215
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
J Gerontol A Biol Sci Med Sci. 2019 Oct 4;74(11):1771-1777
pubmed: 30668637

Auteurs

Francesc Orfila (F)

Unitat de Suport a la Recerca Barcelona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Gran Via Corts Catalanes 587, Àtic, 08007, Barcelona, Spain. forfila.bcn.ics@gencat.cat.
Gerència Territorial de Barcelona, Institut Català de la Salut, Barcelona, Spain. forfila.bcn.ics@gencat.cat.

Lucía A Carrasco-Ribelles (LA)

Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain.

Rosa Abellana (R)

Department of Clinical Foundations, Faculty of Medicine, Barcelona University, Barcelona, Spain.

Albert Roso-Llorach (A)

Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain.
Programa de Doctorat en Metodologia de la Recerca Biomèdica i Salut Pública, Universitat Autònoma de Barcelona, Bellaterra, (Cerdanyola del Vallès), Spain.

Francisco Cegri (F)

Centre d'Atenció Primària Sant Martí de Provençals, Gerència Territorial de Barcelona, Institut Català de la Salut, Barcelona, Spain.

Carlen Reyes (C)

Unitat de Suport a la Recerca Barcelona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Gran Via Corts Catalanes 587, Àtic, 08007, Barcelona, Spain.
Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain.
GREMPAL Research Group, CIBERFes and Idiap Jordi Gol, Instituto de Salud Carlos III and Universitat Autonoma de Barcelona, Barcelona, Spain.

Concepción Violán (C)

Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain.
Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH